Zhu Yanqing, Usui Hitomi Kataoka, Sharma Kumar
Center for Novel Therapies in Kidney Disease, Dorrance Hamilton Research Laboratories, Division of Nephrology, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA.
Semin Nephrol. 2007 Mar;27(2):153-60. doi: 10.1016/j.semnephrol.2007.01.008.
The recognition that the drivers of matrix accumulation is an appropriate therapeutic target for diabetic nephropathy is now accepted by the nephrology and pharmaceutical communities. Interventions focused around transforming growth factor-beta (TGF-beta) likely will be an important area of clinical investigation in the near future. Understanding the various pathways involved in stimulating TGF-beta in the diabetic kidney is of paramount importance in devising strategies to combat the development and progression of diabetic nephropathy. In this review we highlight the major pathways involved in stimulating TGF-beta production by increased glucose levels and discuss the therapeutic implications thereof.
基质蓄积的驱动因素是糖尿病肾病的一个合适治疗靶点,这一认识现已被肾脏病学界和制药界所接受。围绕转化生长因子-β(TGF-β)的干预措施在不久的将来可能会成为临床研究的一个重要领域。了解糖尿病肾脏中刺激TGF-β的各种途径对于制定对抗糖尿病肾病发生和发展的策略至关重要。在本综述中,我们重点介绍了高血糖水平刺激TGF-β产生所涉及的主要途径,并讨论了其治疗意义。